Please login to the form below

Not currently logged in
Email:
Password:

monoclonal antibodies

This page shows the latest monoclonal antibodies news and features for those working in and with pharma, biotech and healthcare.

Bicycle Therapeutics looks to raise $86m with IPO

Bicycle Therapeutics looks to raise $86m with IPO

Chief executive Kevin Lee. Established in 2015, the company’s platform is based on the monoclonal antibodies science conducted by Sir Greg Winter and Professor Christian Heinis, and the company is

Latest news

More from news
Approximately 2 fully matching, plus 78 partially matching documents found.

Latest Intelligence

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    The recent failed phase 3 trial of a combination of MSD’s monoclonal antibody Keytruda (pembrolizumab) and InCyte Corporation’s epacadostat in metastatic melanoma is a case in point he says. ... This has shaped industry development strategies, said

  • The good, the bad and the ugly The good, the bad and the ugly

    Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.

  • The tipping point The tipping point

    For example, since 2015, when the first monoclonal antibody biosimilar, infliximab, was launched in Europe we have seen a notable increase in the overall use of infliximab. ... For example, providing therapeutic drug monitoring (TDM) to minimise loss of

  • What makes the difference in the biosimilar battle? What makes the difference in the biosimilar battle?

    Taking the example of multiple blockbuster monoclonal antibodies close to their patent expiry dates, we can see that numerous big pharma companies like Merck, Amgen and Pfizer and even smaller to

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... The other two companies, the Swedish company, BioInvent, and the British company, Abzena, have

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

  • F-star appoints GSK's Neil Brewis F-star appoints GSK's Neil Brewis

    Brewis joins from GlaxoSmithKline where he served as vice president and head head of biopharmaceutical research, leading a global team of 300 scientists who advanced numerous monoclonal antibodies, antibody fragments, and

  • V Bryan Lawlis joins board of KaloBios V Bryan Lawlis joins board of KaloBios

    patient-targeted, monoclonal antibodies towards commercialisation,” said David Pritchard, president and CEO of KaloBios. ... This includes three antibodies in development: one for inflammatory disease, one for lung infection and one for cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics